MY
Michael Yee
Compare →Global Head of Biotechnology Research & Senior Pharma and Biotech Analyst, UBS
Michael Yee is the Global Head of Biotechnology Research at UBS and a Senior Pharma and Biotech Analyst with over 25 years of experience in Healthcare Equity Research. He has been recognized as a top-ranked analyst in the Institutional Investor /Extel annual poll and has previously held senior positions at Jefferies LLC and RBC Capital Markets.
No chart yet. A chart needs 8 resolved predictions, and Michael has 7. The predictions themselves are below.
SORT
STILL OPEN
?
Pharma stocks are set to take off this year
Due Dec 31, 2026January 8, 2026PharmaStocksPending
—
SCORE
?
Gilead’s weekly oral regimens and annual PrEP dosing with Yeztugo will position the company to offer more convenient options than emerging competitors by 2027–2028.
Due Dec 31, 2028July 29, 2026PrEPPharmaceuticalsPending
—
SCORE
?
Gilead should reach the market around 2031 and remain a leading player in long‑acting HIV treatment.
Due Dec 31, 2031July 29, 2026HIVPharmaceuticalsPending
—
SCORE
RESOLVED · NEWEST FIRST
◇
Commercial market sales in the U.S. could reach $1.5 billion in the fall and winter.
August 3, 2023vaccine salesCOVID-19No verdict
—
SCORE
✓
COVID-19 vaccine could generate sales of more than $5 billion a year
July 13, 2020call #3COVID-19Vaccine SalesCorrect
85
SCORE
✓
the Street will be surprised to the upside if the Covid-19 vaccine works, gets approved by early 2021, and there are multi-billion dollars of purchase orders from USA and around the world
July 13, 2020call #4COVID-19Vaccine ApprovalCorrect
82
SCORE
✓
mRNA-1273 will get at least an emergency use authorization by early next year
July 13, 2020call #5COVID-19Vaccine AuthorizationCorrect
82
SCORE
✓
the vaccine will work and get at least emergency approval by early 2021
July 13, 2020call #6Health CareVaccineCorrect
85
SCORE
◑
the vaccine will get approved and could do over $5 billion in orders over the next few years
July 13, 2020call #7Health CareVaccinePartial
82
SCORE
✓
more investors will start coming back into the biotech space
March 7, 2017call #2biotechinvestorsCorrect
78
SCORE
✗
Sign in to read this call.
June 19, 2015call #1BiotechM&AWrong
7
SCORE
✓
Sign in to read this call.
own side · their own organization · resolved, earns no score
June 19, 2015BiotechInvestmentCorrect
—
SCORE
Still open · 3
THE FRONT EDGENot resolved, so they don’t move the score.
?No market prices this claim
Pharma stocks are set to take off this year
Due Dec 31, 2026Said January 8, 2026PharmaStocks
?No market prices this claim
Gilead’s weekly oral regimens and annual PrEP dosing with Yeztugo will position the company to offer more convenient options than emerging competitors by 2027–2028.
Due Dec 31, 2028Said July 29, 2026PrEPPharmaceuticals
?No market prices this claim
Gilead should reach the market around 2031 and remain a leading player in long‑acting HIV treatment.
Due Dec 31, 2031Said July 29, 2026HIVPharmaceuticals